@article{4a2b802ce8224bd6b0bf014a76c67272,
title = "PARP inhibitors in prostate cancer: time to narrow patient selection?",
keywords = "PARP inhibitors, metastatic castration-resistant prostate cancer, niraparib, olaparib, prostate cancer, rucaparib, talazoparib",
author = "Markowski, {Mark C.} and Antonarakis, {Emmanuel S.}",
note = "Funding Information: This work was partially supported by National Institutes of Health Cancer Center Support Grant P30CA006973 (E.S.A.) and a Prostate Cancer Foundation Young Investigator Award (M.C.M).",
year = "2020",
doi = "10.1080/14737140.2020.1781622",
language = "English (US)",
pages = "523--526",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Taylor and Francis Ltd.",
}